幽门螺杆菌根除治疗对幽门螺杆菌阳性的功能性消化不良患者疗效分析(1)
摘 要：目的 探讨幽门螺杆菌根除治疗对幽门螺杆菌阳性的功能性消化不良(FD)患者疗效。方法 选取2015年1月～2017年1月在本院就诊的幽门螺杆菌阳性的功能性消化不良患者82例，随机分为观察组和对照组。对照组40例采取常规药物(莫沙必利+奥美拉唑)治疗，观察组42例采取四联疗法(兰索拉唑+阿莫西林+克拉霉素+胶体次枸橼酸铋)杀灭幽门螺杆菌治疗，比较两组患者症状改善、临床疗效和不良反应发生情况。结果 两组患者治疗后临床症状积分较治疗前均明显降低，观察组治疗后临床症状积分为(2.71±1.86)分，低于对照组的(8.45±1.92)分，差异有统计学意义(P<0.05)；观察组不良反应发生率(11.90%)明显低于对照组(22.50%)，差异有统计学意义(P<0.05)；观察组总有效率(92.86%)明显高于对照组(75.00%)，差异有统计学意义(P<0.05)。结论 对于幽门螺杆菌阳性的功能性消化不良患者而言，采取四联疗法杀灭幽门螺杆菌，能更加明显改善其临床症状，提高治疗效果，减少不良反应情况，具有临床推广应用价值。
关键词：幽门螺杆菌根除；功能性消化不良；四联疗法；不良反应
, 百拇医药
中图分类号：R57 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.04.024
文章编号：1006-1959(2018)04-0075-03
Abstract：Objective To investigate the efficacy of Helicobacter pylori eradication therapy in the treatment of Helicobacter pylori positive patients with functional dyspepsia(FD).Methods From January 2015 to January 2017，82 patients with Helicobacter pylori positive functional dyspepsia were selected.They were randomly divided into observation group and control group.40 patients in the control group were treated with conventional drugs(mosapride+omeprazole).42 patients in the observation group were treated with tetralogy (lansoprazole+amoxicillin+clarithromycin+colloidal bismuth subcitrate)to kill Helicobacter pylori and make comparison of symptom improvement， clinical efficacy and adverse reactions between the two groups.Results The score of clinical symptom in both groups after treatment was significantly lower than that before treatment，and the clinical symptom score in the observation group was(2.71±1.86)points lower than that in the control group(8.45±1.92)，the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group(11.90%)was significantly lower than that in the control group(22.50%)，the difference was statistically significant(P<0.05).The total effective rate(92.86%)in the observation group was significantly higher than that in the control group(75.00%)，the difference was statistically significant(P<0.05).Conclusion For Helicobacter pylori positive functional dyspepsia patients， taking quadruple therapy to kill Helicobacter pylori can more obviously improve its clinical symptoms，improve the therapeutic effect and reduce the adverse reactions， and has clinical application value.
, 百拇医药
Key words：Helicobacter pylori eradication；Functional dyspepsia；Tetralogy；Adverse reactions
功能性消化不良(functional dyspepsia，FD)是一種多发性消化系统症候群，其临床表现为早饱、恶心呕吐、烧心、嗳气、腹胀反酸、持续性或间歇性上腹疼痛、“出虚恭”等上消化道症状。目前，该病发病机制尚不明确，传统的治疗方式多以抑酸剂和促动力剂联合应用为主，但因极易造成患者情绪异常，疗效并不显著[1]。而近年来多数研究发现，FD的主要病因与幽门螺杆菌(helicobacter pylori，Hp)感染有关[2]，同时自2003年中华医学会消化病学分会后，我国已经就支持部分FD进行Hp根除形成共识。现阶段临床治疗FD多采取Hp根除即四联疗法(质子泵抑制剂+抗生素+铋剂)治疗，疗效确切，可有效改善功能性消化不良患者临床症状，并减少避免其不良反应情况发生。部分国外研究发现，Hp根除对于FD治疗效果较传统治疗方法效果更佳，但国内相关研究较少[3]。本次研究为进一步探讨四联疗法杀灭Hp治疗对FD患者临床疗效的影响，选取了2015年1月～2017年1月82例在本院接受治疗的Hp阳性FD患者作为研究对象，并取得较为满意的成效，现将结果报道如下。, http://www.100md.com(邱君旗)
关键词：幽门螺杆菌根除；功能性消化不良；四联疗法；不良反应
, 百拇医药
中图分类号：R57 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.04.024
文章编号：1006-1959(2018)04-0075-03
Abstract：Objective To investigate the efficacy of Helicobacter pylori eradication therapy in the treatment of Helicobacter pylori positive patients with functional dyspepsia(FD).Methods From January 2015 to January 2017，82 patients with Helicobacter pylori positive functional dyspepsia were selected.They were randomly divided into observation group and control group.40 patients in the control group were treated with conventional drugs(mosapride+omeprazole).42 patients in the observation group were treated with tetralogy (lansoprazole+amoxicillin+clarithromycin+colloidal bismuth subcitrate)to kill Helicobacter pylori and make comparison of symptom improvement， clinical efficacy and adverse reactions between the two groups.Results The score of clinical symptom in both groups after treatment was significantly lower than that before treatment，and the clinical symptom score in the observation group was(2.71±1.86)points lower than that in the control group(8.45±1.92)，the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group(11.90%)was significantly lower than that in the control group(22.50%)，the difference was statistically significant(P<0.05).The total effective rate(92.86%)in the observation group was significantly higher than that in the control group(75.00%)，the difference was statistically significant(P<0.05).Conclusion For Helicobacter pylori positive functional dyspepsia patients， taking quadruple therapy to kill Helicobacter pylori can more obviously improve its clinical symptoms，improve the therapeutic effect and reduce the adverse reactions， and has clinical application value.
, 百拇医药
Key words：Helicobacter pylori eradication；Functional dyspepsia；Tetralogy；Adverse reactions
功能性消化不良(functional dyspepsia，FD)是一種多发性消化系统症候群，其临床表现为早饱、恶心呕吐、烧心、嗳气、腹胀反酸、持续性或间歇性上腹疼痛、“出虚恭”等上消化道症状。目前，该病发病机制尚不明确，传统的治疗方式多以抑酸剂和促动力剂联合应用为主，但因极易造成患者情绪异常，疗效并不显著[1]。而近年来多数研究发现，FD的主要病因与幽门螺杆菌(helicobacter pylori，Hp)感染有关[2]，同时自2003年中华医学会消化病学分会后，我国已经就支持部分FD进行Hp根除形成共识。现阶段临床治疗FD多采取Hp根除即四联疗法(质子泵抑制剂+抗生素+铋剂)治疗，疗效确切，可有效改善功能性消化不良患者临床症状，并减少避免其不良反应情况发生。部分国外研究发现，Hp根除对于FD治疗效果较传统治疗方法效果更佳，但国内相关研究较少[3]。本次研究为进一步探讨四联疗法杀灭Hp治疗对FD患者临床疗效的影响，选取了2015年1月～2017年1月82例在本院接受治疗的Hp阳性FD患者作为研究对象，并取得较为满意的成效，现将结果报道如下。, http://www.100md.com(邱君旗)